Silexion Therapeutics CORP 10-Q quarterly reports

Silexion Therapeutics Corp. filed its Q2 2026 Form 10-Q, detailing increased R&D expenses for its SIL204 trial, ongoing financing efforts, and substantial doubt regarding its ability to continue as a going concern.

Silexion Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of SIL204 and significant capital raising efforts to address going concern risks.

Silexion Therapeutics Corp. reported a significant reduction in net loss and a substantial increase in cash reserves for the nine months ended September 30, 2025, while addressing Nasdaq listing compliance and ongoing financing needs.

Silexion Therapeutics reported an increased net loss in Q2 2025, actively pursuing multiple financing strategies and navigating Nasdaq listing compliance challenges.

Silexion Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Silexion Therapeutics Corp reports its Q3 2024 results, reflecting the impact of its recent business combination and ongoing development of its cancer treatments.

Silexion Therapeutics, a clinical-stage biotechnology company, reported increased net losses for the second quarter of 2024 as it continues to invest heavily in the research and development of its lead pancreatic cancer treatment candidate, SIL-204B.